System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Prof Thierry Passeron is an expert in Dermatology at Centre Hospitalier Universitaire de Nice (France). As of October 2026, ScienceLeadR ranks Thierry Passeron in the top 1% of experts worldwide for Pigmentation Disorders, Alopecia and Hair Diseases. Thierry Passeron has authored 646 publications, the most recent in 2026, and is an investigator in 86 clinical trials, 30 of them ongoing. SLR score: 4,781 (community average: 125). How the SLR is computed.

LeadR Profile

Prof Thierry Passeron Centre Hospitalier Universitaire de Nice France
4 781 ScienceLeadR Reputation 4781

Unlock

Register Login
Network Map

Dermatology

Subspecialties: Public Health - Pharmacy - Infectiology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 1999 - 2026
Source: PubMed

Hôpital l'Archet

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 646

Citations

Citations: 12 507 1st author: 101 Last author: 186 Unique author: 31

Main journals

Ann Dermatol Venereol 112
J Eur Acad Dermatol Venereol 85
Br J Dermatol 51
J Am Acad Dermatol 47
J Invest Dermatol 31

Best Journals

N Engl J Med 4
J Clin Oncol 3
Lancet 2

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The Safety of Melasma Treatment in Vitiligo Patients: An International E-Delphi Study.
PMID 42901881 — safety, tranexamic acid, vitiligo, therapeutics		Pigment Cell Melanoma Res20260
Beyond UV: Visible Light and Pigmentation.
PMID 42802407 — skin, opsins, phototherapy, melanocytes, hyperpigmentation, sunscreening agents, immunity, therapeutics, pigmentation, dermatology		Photodermatol Photoimmunol Photomed20260
Early systemic intervention for vitiligo: A prospective bicentric interventional study.
PMID 42788257 — early medical intervention, skin, sexually transmitted diseases, vitiligo, adrenal cortex hormones, melanocytes, therapeutics, wounds and injuries		J Eur Acad Dermatol Venereol20260
Real-World Treatment Patterns, Healthcare Resource Utilisation, and Costs in Biologic-Naïve Patients with Moderate-to-Severe Psoriasis Treated with Biologics in France.
PMID 42622792 — therapeutics, psoriasis		Dermatol Ther (Heidelb)20260
Efficacy and safety of upadacitinib in adults and adolescents for treatment of non-segmental vitiligo (Viti-Up): results of two phase 3 randomised controlled studies.
PMID 42594914 — skin, safety, vitiligo, adolescent, herpes zoster, therapeutics		Lancet Top journal20263

Clinical Studies 86

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 42

By phase:

Phase 2 33
N/A 23
Phase 3 21
Phase 2/Phase 3 6
Phase 1 1
Phase 1/Phase 2 1
Phase 4 1

By status:

Completed 42
Recruiting 20
Active not recruiting 11
Terminated 7
Unknown 4
Not yet recruiting 2

By type:

Interventional 82
Observational 4

By Monocentric/Multicentric:

monocentric 32
multicentric2to4 12
multicentric5to9 9
multicentricup10 33

Main Topics

Cohort/Consortium Investigators 1

Ongoing Clinical Trials

30 ongoing trials started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
A study to learn how safe bimekizumab is and how well it works in adults with palmoplantar pustulosis
2024-520337-80-00 — safety		Phase 3Recruiting2026
Long term Efficacy and Safety Extension (LTE) Study of Barzolvolimab in Participants with Chronic Spontaneous Urticaria
2025-522878-36-00 — safety, urticaria, therapeutics		Phase 3Not yet recruiting2026
A Study of Baricitinib (LY3009104) in Children From 6 Years to Less Than 18 Years of Age With Alopecia Areata (BRAVE AA PEDS)
2022-502700-78-00 — safety, alopecia areata, child, alopecia, pharmacokinetics		Phase 3Active not recruiting2023
A study to test whether spesolimab helps people with a skin condition called pyoderma gangrenosum
2024-514306-31-00 — skin, safety, multiple chronic conditions, therapeutics, pyoderma, pyoderma gangrenosum		Phase 3Recruiting2025
A clinical trial to learn more about the effects of GIA632 in people with the most common type of vitiligo
2025-522301-37-00 — safety, vitiligo		Phase 2Recruiting2026

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS